REQUEST E-APPLICATION FORM | 01244 746000 | Log in
Don’t invest unless you’re prepared to lose all your money.
These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more.
Investments in unquoted companies carry high risks and investors could lose all funds invested. No established market exists for the trading of shares in private companies, making it difficult to sell shares. The value of tax reliefs depend on personal circumstances and may be subject to change in the future. Investors are encouraged to take independent legal, tax and financial advice before considering an investment.
By clicking below, you confirm that you are an FCA authorised firm or individual and agree to be directed to our website, which is for FCA authorised firms and individuals only. Persons who do not meet this classification should leave this page.
If you are not a professional financial adviser, please contact the Deepbridge Investor Relations Team on 01244 746000 or by email at enquiries@deepbridgecapital.com.
Deepbridge has recently deployed an investment of £250,000 into Levitex Foams Limited, through the Deepbridge Life Sciences EIS fund. This follows on from an initial seed funding investment of £150,000, via the Deepbridge Life Sciences SEIS fund.
Deepbridge have recently deployed an investment of £150,000 into Mynurva Limited, through the Deepbridge Life Sciences SEIS portfolio.
Mynurva Limited aims to transform behavioural health by using technology to make high quality, reliable behavioural healthcare care accessible anywhere, discreetly and securely.
Ian Warwick has been shortlisted for 'Dealmaker of the Year' at the upcoming North West Business Insider Dealmaker Awards.
Taking place at Manchester Central on Thursday 18 October, the awards provide an opportunity to celebrate the achievements of the North West's corporate M&A professionals.
You can see the full shortlist here.
Deepbridge Innovation SEIS and Deepbridge Life Sciences SEIS have therefore been updated accordingly. Please find links to documentation below.
Both propositions are evergreen opportunities with regular deployments usually on a 6-monthly basis.
In August, HM Treasury confirmed the Commencement regulations for the Finance Act 2018, which make changes to the Enterprise Investment Scheme. The Information Memorandum for both the Deepbridge Technology Growth EIS and Deepbridge Life Sciences EIS have therefore been updated accordingly. Please find links to the updated documentation below.
Deepbridge would like to introduce our new SEIS Product Overview Brochures; giving you a chance to look at both our SEIS propositions, The Deepbridge Innovation SEIS and The Deepbridge Life Sciences SEIS, in a more summarised, yet informative, manner.
Deepbridge would like to introduce our new EIS Product Overview Brochures; giving you a chance to look at both our EIS propositions, The Deepbridge Technology Growth EIS and The Deepbridge Life Sciences EIS, in a more summarised, yet informative, manner.
Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.
What are the key risks?
1. You could lose all the money you invest
2. You are unlikely to be protected if something goes wrong
3. You won’t get your money back quickly
4. Don’t put all your eggs in one basket
5. The value of your investment can be reduced
If you are interested in learning more about how to protect yourself, visit the FCA’s website here. [https://www.fca.org.uk/investsmart]
